Selected article for: "cell dhodh and DHODH inhibitor"

Author: Qi Liu; Amita Gupta; Ayse Okesli-Armlovich; Wenjie Qiao; Curt R. Fischer; Mark Smith; Jan E. Carette; Michael C. Bassik; Chaitan Khosla
Title: Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism
  • Document date: 2020_3_25
  • ID: 1zk64gsg_29
    Snippet: The flaviviruses, including dengue virus, are an important class of clinically-relevant viral pathogens with limited treatment options (Boldescu et al., 2017) . In particular, dengue causes hundreds of millions of symptomatic infections annually yet lacks any antiviral treatment while the sole approved vaccine has limited use because of safety risks associated with vaccination of individuals not previously exposed to dengue (Lim et al., 2013; Sri.....
    Document: The flaviviruses, including dengue virus, are an important class of clinically-relevant viral pathogens with limited treatment options (Boldescu et al., 2017) . In particular, dengue causes hundreds of millions of symptomatic infections annually yet lacks any antiviral treatment while the sole approved vaccine has limited use because of safety risks associated with vaccination of individuals not previously exposed to dengue (Lim et al., 2013; Sridhar et al., 2018) . A series of high-throughput phenotypic cell-based screens have recently identified DHODH inhibition as a potent, broadspectrum antiviral strategy in vitro (Hoffmann et al., 2011; Lucas-Hourani et al., 2013; Luthra et al., 2018; Wang et al., 2011) . Furthermore, a DHODH inhibitor was recently shown to suppress SARS-CoV-2 in vitro (Xiong et al., 2020) . However, DHODH inhibitors often lose antiviral activity upon extracellular uridine addition due presumably to pyrimidine salvage (Deans et al., 2016) .

    Search related documents:
    Co phrase search for related documents
    • antiviral activity and cell base: 1
    • antiviral activity and dengue virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and dengue virus include: 1, 2
    • antiviral activity and DHODH inhibitor: 1
    • antiviral activity and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and important class: 1
    • antiviral strategy and approved vaccine: 1, 2, 3, 4, 5
    • antiviral strategy and dengue virus: 1, 2, 3, 4, 5, 6, 7
    • antiviral strategy and high throughput: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral treatment and approved vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral treatment and dengue virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • antiviral treatment and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • antiviral treatment and important class: 1
    • approved vaccine and dengue virus: 1, 2, 3, 4, 5, 6, 7
    • approved vaccine and high throughput: 1, 2, 3, 4
    • cell base and high throughput: 1
    • dengue virus and DHODH inhibitor: 1
    • dengue virus and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • dengue virus and important class: 1